Literature DB >> 3020693

Therapy with cisplatin and etoposide for non-small-cell lung cancer.

J Klastersky.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3020693

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  10 in total

1.  Phase II study of mitomycin C, etoposide and vindesine in metastatic stage IV non-small-cell lung cancer.

Authors:  C Gridelli; R Pepe; S Palmeri; S Iacobelli; M Gentile; V Gebbia; C Garufi; G Airoma; G Palmieri; A Russo
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  Carboplatin in combination with etoposide in inoperable non-small-cell lung cancer (NSCLC).

Authors:  P Weynants; Y Humblet; A Bosly; D Schallier; P Duprez; F Majois; M Beauduin; J Prignot; M Symann
Journal:  Med Oncol Tumor Pharmacother       Date:  1990

3.  Phase II study of carboplatin in untreated, inoperable non-small-cell lung cancer.

Authors:  U Gatzemeier; M Heckmayr; D K Hossfeld; R Zschaber; W Achterrath; L Lenaz
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  Pharmacokinetics and toxicity of two modalities of etoposide infusion in metastatic non-small-cell lung carcinoma.

Authors:  E Chatelut; C Chevreau; E Blancy; A Lequellec; P Canal; H Roche; G Houin; R Bugat
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

5.  Randomized, multi-center phase II trial of docetaxel plus cisplatin versus etoposide plus cisplatin as the first-line therapy for patients with advanced non-small cell lung cancer.

Authors:  Nam-Su Lee; Hee-Sook Park; Jong-Ho Won; Dae-Sik Hong; Su-Taek Uh; Sang-Jae Lee; Joo-Hang Kim; Se-Kyu Kim; Myung-Ju Ahn; Jung-Hye Choi; Suk-Chul Yang; Jung-Ae Lee; Keun-Seok Lee; Chang-Yeol Yim; Yong-Chul Lee; Chul-Soo Kim; Moon-Hee Lee; Kab-Do Jung; Hanlim Moon; Yl-Sub Lee
Journal:  Cancer Res Treat       Date:  2005-12-31       Impact factor: 4.679

Review 6.  Vinorelbine. A review of its antitumour activity in lung cancer.

Authors:  J B Sørensen
Journal:  Drugs       Date:  1992       Impact factor: 9.546

7.  Mitomycin C plus vindesine or cisplatin plus epirubicin in previously treated patients with symptomatic advanced non-small-cell lung cancer.

Authors:  C Gridelli; G Airoma; P Incoronato; R Pepe; G Palazzolo; A Rossi; A R Bianco
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

8.  Phase II study of a 72-h concurrent continuous infusion of cisplatin and etoposide in advanced non-small-cell lung cancer.

Authors:  H Saito; K Shimokata; M Yamamoto; H Saka; S Sakai; H Saito
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  A prognostic-factor risk index in advanced non-small-cell lung cancer treated with cisplatin-containing combination chemotherapy.

Authors:  T Shinkai; K Eguchi; Y Sasaki; T Tamura; Y Ohe; A Kojima; F Oshita; T Miya; H Okamoto; K Iemura
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

10.  Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer.

Authors:  J H M Schellens; A S T Planting; N van Zandwijk; J Ma; M Maliepaard; M E L van der Burg; M de Boer-Dennert; E Brouwer; A van der Gaast; M J van den Bent; J Verweij
Journal:  Br J Cancer       Date:  2003-03-24       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.